GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 283.00
Bid: 279.00
Ask: 283.00
Change: -7.00 (-2.41%)
Spread: 4.00 (1.434%)
Open: 285.00
High: 285.00
Low: 279.00
Prev. Close: 290.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS REPORTS: Elementis swings to profit; Hutchmed changes CEO

Thu, 03rd Mar 2022 13:02

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Elementis PLC - London-based speciality chemicals - Swings to profit in 2021, with pretax profit of USD5.8 million, up from a loss of USD68.8 million in 2020. Strong new business momentum, targeted pricing actions and volume recovery boost revenue by 17% in the year to USD880 million from USD751 million the year before. Dividends may be reinstated in the medium term, but remain suspended. For 2022, global supply chain issues and cost inflation are a concern, but it is off to "an encouraging start".

----------

Synthomer PLC - Essex-based chemicals company - Profit before tax rockets in 2021 to GBP283.9 million from GBP20.3 million in 2020, as revenue is up 42% to GBP2.33 billion from GBP1.64 billion. Underlying pretax profit more than doubles to GBP420.1 million from GBP160.0 million. Profit is being used to make "major inorganic and organic investments" to support further growth. In 2022 so far, nitrile latex demand is "subdued" as Covid eases and inventories of medical gloves are high, while all other divisions have started 2022 well. Final dividend is 21.3 pence, over double that of 8.3p in 2020, for a total in 2021 of 30.0p, up from 11.6p the prior year.

----------

Glanbia PLC - Kilkenny, Ireland-based nutrition company - Revenue comes in ahead of expectations for 2021 at EUR4.20 billion, up 9.8% from EUR3.82 billion in 2020. Profit before tax rises 21% to EUR158.0 million from EUR131.1 million. Says performance was driven by strong global consumer demand. A final dividend of 17.53 cents is proposed, bringing the year's total to 29.28 cents, up 10% on 2020, and launches new EUR50 million share buyback. Growth in revenue is expected for 2022, and says inflationary costs will be managed with higher sales prices.

----------

Galliford Try Holdings PLC - Uxbridge, England-based construction company - Pretax profit up to GBP7.1 million in first half ended December 31 from GBP4.1 million a year before. Revenue is up 10% to GBP594 million from GBP542 million in the prior year. Order book is up to GBP3.4 billion from GBP3.3 billion a year ago. The company boosts interim dividend by 83% to 2.2 pence from 1.2p the year before. Outlook for the rest of the year is positive, with 95% of projected revenue already secured.

----------

Empiric Student Property PLC - London-based owner and operator of student accommodation - Swings to profit in 2021, with a pretax profit of GBP29.2 million from a pretax loss of GBP24.0 million. Net rental inome drops 11% year-on-year to GBP32.9 million from GBP32.9 million, with total revenue down 6% to GBP56.0 million from GBP59.4 million. Dividends resume in fourth quarter, with payment of 2.5p, and targets fully covered and progressive dividends going forward, to increase as occupancy rates normalise. For the academic year starting in 2022, Empiric expects to come in at the top of its 85% to 95% target occupancy rate.

----------

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical company - Total revenue for 2021 is USD356.1 million up 56% year-on-year from USD228.0 million. Loss before tax of USD215.7 million widens from USD189.7 million in FY20. Momentum is continuing into 2022, and it held over USD1 billion in cash on December 31. Christian Hogg retires as chief executive officer, after 22 years with the company and 15 years as CEO. Promotes Chief Scientific Officer Weiguo Su, a 17-year company veteran, to CEO. The changes are effective from Friday.

----------

AIB Group PLC - Dublin-based bank - Swings to pretax profit of EUR629 million in 2021 from a loss of EUR931 million. Net interest income drops 4% to EUR1.79 billion from EUR1.87 billion the prior year. Gross loans were down 2% to EUR56.5 billion from EUR59.4 billion. Recommends dividend of 4.5 pence per share for the year, with no dividend having been paid in 2021. AIB expects net interest income to be "stable" in 2022.

----------

Hunting PLC - London-based energy services - In 2021, revenue drops 17% to USD521.6 million from USD626.0 million in 2020, but pretax loss from operations narrows to USD85.5 million from USD223.0 million. Second half of 2021 lifted by improved trading and recovering commodity prices, after first half hit by global reduction in activity in oil & gas. A final dividend of 4.0 cents will be paid out for the year, unchanged from 2020. As Covid-related operational issues ease in its first quarter, it predicts a "much improved" 2022.

----------

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
21 Feb 2024 15:14

UK earnings, trading statements calendar - next 7 days

Thursday 22 February 
Anglo American PLCFull Year Results
Genus PLCHalf Year Results
Hargreaves Lansdown PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Indivior PLCFull Year Results
Jupiter Fund Management PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
ME Group International PLCFull Year Results
Mondi PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
WPP PLCFull Year Results
Friday 23 February 
City of London Investment Group PLCHalf Year Results
Irish Residential Properties REIT PLCFull Year Results
Standard Chartered PLCFull Year Results
Monday 26 February 
Base Resources LtdHalf Year Results
Bunzl PLCFull Year Results
EnSilica PLCHalf Year Results
Kosmos Energy LtdFull Year Results
Made Tech Group PLCHalf Year Results
Tristel PLCHalf Year Results
Tuesday 27 February 
abrdn Equity Income Trust PLCFull Year Results
abrdn PLCFull Year Results
Croda International PLCFull Year Results
Kitwave Group PLCFull Year Results
McBride PLCHalf Year Results
PCI-PAL PLCHalf Year Results
Smith & Nephew PLCFull Year Results
Synectics PLCFull Year Results
Uniphar PLCFull Year Results
Unite Group PLCFull Year Results
Wednesday 28 February 
AB Dynamics PLCTrading Statement
ASA International Group PLCTrading Statement
Aston Martin Lagonda Global Holdings PLCFull Year Results
Avingtrans PLCHalf Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Derwent London PLCFull Year Results
Glenveagh Properties PLCFull Year Results
Grit Real Estate Income Group LtdHalf Year Results
Hutchmed China LtdFull Year Results
International Personal Finance PLCFull Year Results
Just Eat Takeaway.com NVFull Year Results
Primary Health Properties PLCFull Year Results
Reckitt Benckiser Group PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
RHI Magnesita NVFull Year Results
St James's Place PLCFull Year Results
Taylor Wimpey PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
7 Feb 2024 09:50

Hutchmed hails fruquintinib trial results for gastric cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Wednesday said phase three data for fruquintinib in combination with paclitaxel showed an improvement in overall survival for patients with gastric or gastroesophageal junction adenocarcinoma.

Read more
2 Feb 2024 09:52

Hutchmed says Inmagene exercises option to licence drug candidates

(Alliance News) - Hutchmed (China) Ltd on Friday said Inmagene Biopharmaceuticals Ltd has exercised options to licence two drug candidates as part of a strategic partnership.

Read more
2 Feb 2024 09:42

Hutchmed partner Inmagene exercises options over two drug candidates

(Sharecast News) - Hutchmed China announced on Friday that Inmagene Biopharmaceuticals has exercised options to licence two drug candidates, IMG-007 and IMG-004, as part of their strategic partnership.

Read more
30 Jan 2024 10:32

Hutchmed's 'Elunate' approved under new Hong Kong rules

(Sharecast News) - Hutchmed China announced the approval of its drug 'Elunate', or fruquintinib, by the Pharmacy and Poisons Board of Hong Kong on Tuesday, for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC).

Read more
30 Jan 2024 09:20

Hutchmed celebrates cancer drug approval in hometown of Hong Kong

(Alliance News) - Hutchmed (China) Ltd on Tuesday touted progress in Hong Kong, after its oral therapy for metastatic colorectal cancer received marketing approval in the city.

Read more
11 Jan 2024 11:11

Hutchmed application for thrombocytopenia treatment accepted in China

(Sharecast News) - Hutchmed China announced on Thursday that the new drug application (NDA) for sovleplenib, an oral inhibitor targeting spleen tyrosine kinase (Syk), had been accepted for review and granted priority review by China's National Medical Products Administration (NMPA).

Read more
11 Jan 2024 10:17

TOP NEWS: Hutchmed Sovleplenib accepted for review by China drug bureau

(Alliance News) - Hutchmed Ltd on Thursday said that its novel treatment for haematological malignancies and immune diseases had been progressed to the next stage of approval by the country's national bureau for drug supervision.

Read more
21 Dec 2023 11:36

IN BRIEF: Hutchmed China renews deals with "substantial" shareholders

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Agrees with "substantial shareholder" Sinopharm Group Co Ltd to renew the Framework Sinopharm Products Supply & Purchase Agreement, effective from January 1, for three years up to and including December 31, 2026. Also agrees with HCMH to renew the HBYS Brand License Royalty agreement, also effective from January 1 and for the same duration. HCMH entered the HBYS deal in June 2021 with HWEL, a subsidiary of major shareholder CK Hutchison Holdings Ltd which holds an approximate 38.18% stake in Hutchmed.

Read more
13 Dec 2023 13:56

Hutchmed completes enrolment for fruquintinib trial

(Alliance News) - Hutchmed (China) Ltd on Wednesday said it has completed enrolment of its phase II/III trial of fruquintinib.

Read more
13 Dec 2023 12:20

Hutchmed completes trial enrolment, keeps drugs on China funding list

(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.

Read more
13 Dec 2023 12:20

Hutchmed completes trial enrolment, keeps drugs on China funding list

(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.

Read more
9 Nov 2023 12:16

Hutchmed hails Takeda's fruquintinib approval from US for cancer form

(Alliance News) - Hutchmed (China) Ltd on Thursday announced that the Tokyo-based drug maker, Takeda Pharmaceutical Co Ltd, has received US approval of fruquintinib for a form of colorectal cancer.

Read more
29 Sep 2023 10:57

Hutchmed confirms new drug application for fruquintinib in Japan

(Sharecast News) - Hutchmed China announced on Friday that its partner Takeda has officially submitted a new drug application (NDA) for fruquintinib to the Ministry of Health, Labour and Welfare (MHLW) in Japan.

Read more
29 Sep 2023 10:12

Hutchmed notes Takeda submits fruquintinib drug application in Japan

(Alliance News) - Hutchmed (China) Ltd on Friday said Takeda Pharmaceutical Co Ltd has submitted a new drug application for cancer treatment fruquintinib to the Ministry of Health, Labour & Welfare in Japan.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.